ADMA
ADMA Biologics, Inc.
NASDAQHealthcareBiotechnologyUS
Rating:B+
Company Profile
CEO
Adam S. Grossman
IPO Date
2013-10-17
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
ADMA Biologics, Inc.
CEO
Adam S. Grossman
IPO Date
2013-10-17
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 136,363 |
| $8.81 |
| 28 May 2026 | Grossman Jerrold B | director | P-Purchase | Acquired | 6,400 | $7.91 |
| 14 May 2026 | Grossman Jerrold B | director | P-Purchase | Acquired | 12,500 | $8.01 |
| 12 May 2026 | Grossman Jerrold B | director | P-Purchase | Acquired | 12,500 | $8.01 |
| 3 Apr 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | F-InKind | Disposed | 20,362 | $9.11 |
| 17 Mar 2026 | Guiheen Lawrence P. | director | M-Exempt | Acquired | 30,000 | $3.66 |
| 17 Mar 2026 | Guiheen Lawrence P. | director | G-Gift | Disposed | 30,000 | $0.00 |
| 17 Mar 2026 | Guiheen Lawrence P. | director | G-Gift | Acquired | 30,000 | $0.00 |
| 17 Mar 2026 | Guiheen Lawrence P. | director | M-Exempt | Disposed | 30,000 | $3.66 |